Thu, Dec 04, 2025 page2

• NT$100-million NHI coverage for rare disease sparks debate

  • Staff writer, with CNA
  • • 
    • 
    • 

  The National Health Insurance Administration (NHIA) has decided to cover an expensive, but effective gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency, sparking debate over fairness and treatment access for patients with other rare conditions.

  The one-time therapy, which costs about NT$100 million (US$3.28 million) per injection, would be covered on a temporary basis, the NHIA said on Tuesday.

  Its effectiveness would be reassessed three years after treatment begins, and coverage terms may be adjusted as needed.

  

  The National Health Insurance logo is pictured in an undated photograph.

  Photo: Taipei Times

  AADC deficiency affects infants and young children, causing severe developmental delays and autonomic dysfunction.

  Without treatment, many patients die between the ages of two and five, but the therapy can significantly improve motor function and quality of life.

  The treatment was developed by National Taiwan University Hospital (NTUH) in 2007, with clinical protocols established in 2010 before being licensed to a US company.

  The NHIA estimates that 13 patients would receive the therapy in its first year at a cost of about NT$1.3 billion.

  From the second through fifth years, five additional patients are expected to be treated annually, costing about NT$500 million per year.

  The decision has sparked criticism from physicians, including pulmonologist Su Yi-fong (蘇一峰), who said that drugs for other rare diseases — such as lymphangioleiomyomatosis (LAM or "bubble lung") — treat dozens of patients for less than NT$100 million, yet are not fully covered.

  Supporters countered that the AADC therapy offers life-saving benefits and meaningful developmental gains.

  Physician Chiang Kuan-yu (姜冠宇) said the investment could help position Taiwan as a key site for Asian genetic data, supporting future research collaborations and negotiations with international pharmaceutical companies.

  NTUH Department of Medical Genetics director Chien Yin-hsiu (簡穎秀) defended the technology transfer to the US, saying few believed in the feasibility of AADC gene therapy two decades ago.

  There had been no effective treatment for AADC deficiency in the past, and affected children could only lie immobile in bed with no motor development, Chien said.

  Among the 31 patients who received the new therapy in a trial, 80 percent were able to sit up, and among those treated early with intensive rehabilitation, 40 percent were able to walk independently, she said.

  "Just being able to sit up instead of only lying down makes an enormous difference," she said. "For parents providing daily care, the improvement is like night and day."

  Regarding LAM coverage, NHIA Director-General Chen Lian-yu (陳亮妤) said the disease is not currently classified as rare, although applications have been submitted.

  Coverage would follow once the ministry completes its review, she said.

  LAM drugs have been covered under NHI since 2001, with 26 patients reported last year.

  NHIA said it would assist families facing difficulties in the application process.
• Most Popular

  • 1

    First person arrested as Danjiang Bridge opens

  • 2

    TSMC shares stumble on report, but losses minor

  • 3

    Navy needs 12 subs for modern fleet: CSBC head

  • 4

    Snake on a train spooks riders on Taipei MRT line

  • 5

    HIMARS to be deployed to islands